| Theme | Update on Pancreatic Neuroendocrine Tumors | |
|---|---|---|
| Title | Diagnosis and Treatment of Neuclear Medicine for Pancreatic Neuroendocrine Tumors | |
| Publish Date | 2018/08 | |
| Author | Noritoshi Kobayashi | Department of Oncology, Yokohama City University Graduate School of Medicine |
| Author | Shoko Takano | Department of Radiology, Yokohama City University Graduate School of Medicine |
| Author | Tomohiro Kaneta | Department of Radiology, Yokohama City University Graduate School of Medicine |
| Author | Yasushi Ichikawa | Department of Oncology, Yokohama City University Graduate School of Medicine |
| [ Summary ] | Somatostatin receptor scintigraphy (SRS) using 111In-Pentetreotide is a molecular imaging technique for diagnosing somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs). Prior to peptide receptor radio-nuclide therapy (PRRT) for the palliative treatment of unresectable or metastasized NETs, SRS is an indispensable imaging technique. Tumor uptake on SRS could predict the efficacy of PRRT. PRRT is an ideal target treatment for the SSTR positive NETs. We determine the relationship between SRS and PRRT as the typical model of theranostics. | |